Latest Healthcare News

Page 18 of 215
Invex Therapeutics reported promising preclinical findings on Exenatide’s effects in a human Alzheimer's disease model, alongside a steady cash position and reduced operating outflows in Q3 FY26.
Ada Torres
Ada Torres
24 Apr 2026
CLINUVEL Pharmaceuticals has received final scientific advice from the European Medicines Agency on the design of its pivotal Phase III trial for SCENESSE in vitiligo, endorsing a comprehensive evidence approach and prioritising patients with darker skin tones.
Ada Torres
Ada Torres
24 Apr 2026
EBR Systems secures Priority Review from Australia's TGA for its wireless cardiac pacing system, fast-tracking regulatory approval and expanding access for heart failure patients. This follows strong US commercial momentum after FDA approval.
Ada Torres
Ada Torres
24 Apr 2026
Cambium Bio has secured FDA confirmation that a single pivotal Phase 3 trial plus confirmatory evidence will suffice for Biologics License Application submission for Elate Ocular, significantly reducing development expenses and accelerating the pathway to market.
Ada Torres
Ada Torres
23 Apr 2026
InteliCare has inked a $200,000 contract to deploy its AI-powered monitoring platform across 65 retirement villas at Warrigal's new development, marking its first foray into the retirement living sector with potential for wider rollout.
Ada Torres
Ada Torres
23 Apr 2026
Little Green Pharma has pushed back the Federal Court hearing for its Cannatrek acquisition to late May, setting a new timetable that includes a shareholder vote on May 22 and implementation targeted for June 1.
Ada Torres
Ada Torres
23 Apr 2026
Doctor Care Anywhere posted an 8.4% quarterly jump in consultations and sustained positive cashflow for the fourth consecutive quarter, while launching new digital health initiatives and reaffirming its medium-term revenue and profitability targets.
Ada Torres
Ada Torres
23 Apr 2026
Radiopharm Theranostics (ASX: RAD) has completed enrolment in its Phase 2b RAD 101 brain metastases imaging trial with interim data showing 90% concordance with MRI, while progressing early-stage trials of therapeutic candidates RAD 202, RV-01, and RAD 402. The company reported a $19.2 million cash balance at quarter end, down from $34.5 million, with a net operating cash outflow of $14.9 million driven by milestone-related R&D and staff costs.
Ada Torres
Ada Torres
23 Apr 2026
Wellnex Life has pushed back the repayment deadline on nearly $3 million owed to former directors by three months, agreeing to additional fees and interest. Former CEO Zack Bozinovski returns as a consultant, suggesting ongoing strategic recalibration.
Ada Torres
Ada Torres
23 Apr 2026
Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.
Ada Torres
Ada Torres
22 Apr 2026
Alterity Therapeutics has unveiled fresh Phase 2 data revealing ATH434’s ability to slow functional decline in Multiple System Atrophy patients, measured by the novel MuSyCA scale. This reinforces the drug’s disease-modifying potential ahead of pivotal Phase 3 trials.
Ada Torres
Ada Torres
22 Apr 2026
BCAL Diagnostics has expanded its Avantect cancer blood tests nationally through major pathology networks, generating $88,000 in Q3 revenue from 91 tests. The company also submitted an initial Medicare reimbursement application for pancreatic cancer detection and is preparing to launch an enhanced BREASTESTplus 2.0 test in early 2027.
Ada Torres
Ada Torres
22 Apr 2026